Clinical Trial: A Trial Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of CTX460 in Adults With Emphysema Associated With Severe Alpha-1 Antitrypsin Deficiency (AATD)

U.S., Oct. 1 -- ClinicalTrials.gov registry received information related to the study (NCT07850076) titled 'A Trial Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of CTX460 in Adults With Emphysema Associated With Severe Alpha-1 Antitrypsin Deficiency (AATD)' on Sept. 21.

Brief Summary: A Study of CTX460 in Adults with Emphysema Associated with Severe Alpha-1 Antitrypsin Deficiency (AATD).

Study Start Date: Oct. 31

Study Type: INTERVENTIONAL

Condition: Alpha-1 Antitrypsin Deficiency (AATD)

Intervention: DRUG: CTX460

CTX460 is a lipid nanoparticle (LNP) formulation of synthetic nucleotide template polymerase (SyNTase) editor for in vivo gene editing of the serine protease inhibitor A1 (SERPINA1)...